WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Tongzi Women's Federation Promotes SexBoosting Rural Revitalization in HometownS. Korea's opposition party overwhelmingly leads exit polls in parliamentary elections2024 China Internet Media Forum Opens in Yunnan ProvinceTravel Boom Sees 740 Mln Trips Made in 34th China International Consumer Products Expo to Kick off in HainanCrackdown Targets Women, Child TraffickingSerial Short Videos Released to Raise Awareness About Children's CharitiesBoeing plane makes emergency landing after engine cover falls offSmall town thrives with winter games
2.5924s , 6574.8828125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gazetteer news portal